Therapeutic effects of organic zinc on reproductive hormones, insulin resistance and mTOR expression, as a novel component, in a rat model of Polycystic ovary syndrome

被引:15
作者
Torshizi, Faeze Fazel [1 ]
Chamani, Mohammad [1 ]
Khodaei, Hamid Reza [2 ]
Sadeghi, Ali Asghar [1 ]
Hejazi, Seyed Hossein [3 ]
Heravi, Reza Majidzadeh [4 ]
机构
[1] Islamic Azad Univ, Sci & Res Branch, Dept Anim Sci, Tehran, Iran
[2] Islamic Azad Univ, Golpayegan Branch, Dept Anim Sci, Esfahan, Iran
[3] Isfahan Univ Med Sci, Sch Med, Skin Dis & Leishmaniasis Res Ctr, Dept Parasitol & Mycol, Esfahan, Iran
[4] Ferdowsi Univ Mashhad, Dept Anim Sci, Mashhad, Razavi Khorasan, Iran
关键词
Insulin resistance; mTOR; Polycystic ovary syndrome; Rat; Zinc-methionine; MAMMALIAN TARGET; ESTRADIOL VALERATE; SIGNALING PATHWAY; OXIDATIVE STRESS; GENE-EXPRESSION; RAPAMYCIN; GROWTH; SUPPLEMENTATION; IMPROVEMENT; METABOLISM;
D O I
10.22038/IJBMS.2019.36004.8586
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objective(s): Zinc is an effective factor in the reproductive system. Insulin resistance (IR) is known as an important disorder in patients with polycystic ovary syndrome (PCOS). Mammalian target of rapamycin (mTOR), which controls key cell activities, in particular, is activated in disorders such as PCOS. The present study was conducted to observe the therapeutic effects of organic zinc on IR, mTOR gene expression, and pathogenesis of PCOS in a rat model induced-PCOS. Materials and Methods: Experimental treatments were performed on control and treated groups, consisting of healthy controls (Control, water, and standard feed intake and daily injection of sesame oil alone), Polycystic control (PCO, injection of 4 mg/kg estradiol valerate (EV) for four weeks). Treated groups (PCO-ZM 25, PCO-ZM 75, and PCO-ZM 175) after 4 weeks of receiving EV, were daily given three levels of 25, 75, and 175 mg zinc methionine/kg BW for 15 days, respectively. Results: Injection of EV dramatically increased body and ovarian weights, levels of LH, testosterone, estradiol, triglyceride, fasting insulin, fasting glucose, HOMA-IR, IGF-1, gene expression of mTOR, and number of cysts (P<0.05). It also reduced the level of progesterone, HDL-C, and the number of antral follicles (P<0.05). However, by increasing zinc-methionine application especially at 175 mg/kg BW, the induction effects of EV were improved on ovarian cysts (P<0.05). Conclusion: Organic zinc showed beneficial effects in the EV induced PCOS rats via decreased insulin resistance and mTOR expression, restored the hormonal profile, and decreased the number of cysts in the ovaries.
引用
收藏
页码:36 / 45
页数:10
相关论文
共 50 条
  • [21] Therapeutic potentials of the caffeine in polycystic ovary syndrome in a rat model: Via modulation of proinflammatory cytokines and antioxidant activity
    Raoofi, Amir
    Rezaie, Mohammad Jafar
    Delbari, Ali
    Ghoreishi, Seyed Amir-Hossein
    Sichani, Pegah Hadi
    Maleki, Shahram
    Nasiry, Davood
    Akhlaghi, Maedeh
    Ebrahimi, Vahid
    Khaneghah, Amin Mousavi
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2022, 50 (06) : 137 - 146
  • [22] Nicotinamide Mononucleotide Improves Endometrial Homeostasis in a Rat Model of Polycystic Ovary Syndrome by Decreasing Insulin Resistance and Regulating the Glylytic Pathway
    Zhang, Wenhui
    Zhang, Jiaming
    Xue, Haoxuan
    Chen, Xi
    Li, Meixiang
    Chen, Shenghua
    Li, Zhiling
    Sechi, Leonardo Antonio
    Wang, Qian
    Capobianco, Giampiero
    Lei, Xiaocan
    MOLECULAR NUTRITION & FOOD RESEARCH, 2024, 68 (21)
  • [23] Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome
    Belli, SH
    Graffigna, MN
    Oneto, A
    Otero, P
    Schurman, L
    Levalle, OA
    FERTILITY AND STERILITY, 2004, 81 (03) : 624 - 629
  • [24] The relationship between retinol-binding protein 4 levels, insulin resistance, androgen hormones and polycystic ovary syndrome
    Mellati, Ali Awsat
    Sharifi, Faranak
    Sajadinejad, Mohsen
    Sohrabi, Davood
    Mazloomzadeh, Saeideh
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2012, 72 (01) : 39 - 44
  • [25] Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy
    Teede, Helena J.
    Meyer, Caroline
    Hutchison, Samantha K.
    Zoungas, Sophia
    McGrath, Barry P.
    Moran, Lisa J.
    FERTILITY AND STERILITY, 2010, 93 (01) : 184 - 191
  • [26] Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome
    Alan, Murat
    Gurlek, Beril
    Yilmaz, Alpay
    Aksit, Murat
    Aslanipour, Behnaz
    Gulhan, Ibrahim
    Mehmet, Calan
    Taner, Cuneyt Eftal
    GYNECOLOGICAL ENDOCRINOLOGY, 2019, 35 (03) : 220 - 223
  • [27] Screening for Insulin Resistance in Polycystic Ovary Syndrome Views of Physician Members of the American Society for Reproductive Medicine
    Asante, Albert
    Omurtag, Kenan
    Stewart, Elizabeth A.
    Coddington, Charles C.
    JOURNAL OF REPRODUCTIVE MEDICINE, 2015, 60 (9-10) : 371 - 377
  • [28] A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice
    Kauffman, Alexander S.
    Thackray, Varykina G.
    Ryan, Genevieve E.
    Tolson, Kristen P.
    Glidewell-Kenney, Christine A.
    Semaan, Sheila J.
    Poling, Matthew C.
    Iwata, Nahoko
    Breen, Kellie M.
    Duleba, Antoni J.
    Stener-Victorin, Elisabet
    Shimasaki, Shunichi
    Webster, Nicholas J.
    Mellon, Pamela L.
    BIOLOGY OF REPRODUCTION, 2015, 93 (03)
  • [29] The expression of Nuclear Factor-κB in a rat model of polycystic ovary syndrome
    Wang, Hui-lan
    Xu, Xia
    Zheng, Zhi-qun
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2018, 45 (02) : 276 - 279
  • [30] Impaired glucose tolerance and insulin resistance in a prenatally-androgenized rat model of polycystic ovary syndrome in later life
    Farhadi-Azar, Mahbanoo
    Noroozzadeh, Mahsa
    Mousavi, Maryam
    Naz, Marzieh Saei Ghare
    Tehrani, Fahimeh Ramezani
    EXPERIMENTAL PHYSIOLOGY, 2025, 110 (03) : 410 - 423